DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Lucentis (Ranibizumab) - Published Studies

 
 



Lucentis Related Published Studies

Well-designed clinical trials related to Lucentis (Ranibizumab)

Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration. [2011.12]

Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. [2011.10]

PROSPECTIVE RANDOMIZED CONTROLLED TRIAL OF COMBINATION RANIBIZUMAB (LUCENTIS) AND BROMFENAC (XIBROM) FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Pilot Study. [2011.08.20]

Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. [2011.08]

A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab. [2011.07]

Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-Hispanic white population in the United States with age-related macular degeneration. [2011.06]

Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. [2011.06]

Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration. [2011.05]

Long-term efficacy and safety of ranibizumab administered pro re nata in Japanese patients with neovascular age-related macular degeneration in the EXTEND-I study. [2011.05]

Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. [2011.05]

The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. [2011.04]

Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. [2011.04]

Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. [2011.03]

ISRCTN12125882 - Influence of topical anti-VEGF (Ranibizumab) on the outcome of filtration surgery for glaucoma - Study Protocol. [2011.01.17]

Ranibizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration: a phase I clinical trial. [2011.01]

A pilot study on the combination treatment of reduced-fluence photodynamic therapy, intravitreal ranibizumab, intravitreal dexamethasone and oral minocycline for neovascular age-related macular degeneration. [2011]

A review of ranibizumab clinical trial data in exudative age-related macular degeneration and how to translate it into daily practice. [2011]

Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration. [2011]

Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. [2010.11]

Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial. [2010.11]

Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. [2010.11]

Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor study. [2010.10]

Dosing regimen and the frequency of macular hemorrhages in neovascular age-related macular degeneration treated with ranibizumab. [2010.10]

A randomised prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration. [2010.10]

Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. [2010.09]

Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study. [2010.09]

Bleb morphology and vascularity after trabeculectomy with intravitreal ranibizumab: a pilot study. [2010.09]

Prospective one-year study of ranibizumab for predominantly hemorrhagic choroidal neovascular lesions in age-related macular degeneration. [2010.09]

Phase I study of subconjunctival ranibizumab in patients with primary pterygium undergoing pterygium surgery. [2010.06]

Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. [2010.06]

Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. [2010.06]

Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review. [2010.05]

EXTEND-I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. [2010.05]

Effect of brimonidine/timolol fixed combination on preventing the short-term intraocular pressure increase after intravitreal injection of ranibizumab. [2010.04]

Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR. [2010.04]

Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab--a randomized controlled trial. [2010.03]

Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor study. [2010]

Dosing regimen and the frequency of macular hemorrhages in neovascular age-related macular degeneration treated with ranibizumab. [2010]

Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. [2010]

A randomised prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration. [2010]

Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. [2010]

Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials. [2009.12]

Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial. [2009.12]

Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study. [2009.11]

Bevacizumab vs Ranibizumab for Age-related Macular Degeneration: Early Results of a Prospective Double-Masked, Randomized Clinical Trial. [2009.10.02]

A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. [2009.09]

Intravitreal ranibizumab, intravitreal ranibizumab with PDT, and intravitreal triamcinolone with PDT for the treatment of retinal angiomatous proliferation: a prospective study. [2009.04]

Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. [2009.01]

Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. [2009.01]

Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions. [2008.10]

Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. [2007.10]

Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. [2007.02]

Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. [2006.11]

Ranibizumab versus verteporfin for neovascular age-related macular degeneration. [2006.10.05]

Ranibizumab for neovascular age-related macular degeneration. [2006.10.05]

Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. [2006.10]

Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. [2006.04]

Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. [2006.04]

Well-designed clinical trials possibly related to Lucentis (Ranibizumab)

Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. [2012]

Evaluation of masking study participants to intravitreal injections in a randomized clinical trial. [2012]

Treatment of diabetic retinopathy with anti-VEGF drugs. [2011.05]

Patient characteristics and treatment of neovascular age-related macular degeneration in France: the LUEUR1 observational study. [2011.04]

Randomized trial of anesthetic methods for intravitreal injections. [2011.03]

Patient-reported outcomes among sham vs no-treatment controls from randomized trials. [2011.02]

Intravitreal injection anesthesia--comparison of different topical agents: a prospective randomized controlled trial. [2011.02]

An observational retrospective subgroup analysis of verteporfin photodynamic therapy-naive and previously treated patients in the focus trial. [2011.01]

Intravitreal injection anesthesia--comparison of different topical agents: a prospective randomized controlled trial. [2011]

Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: two-year outcomes. [2010.12]

Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion. [2010.10.06]

Vision-related function after low-dose transpupillary thermotherapy versus photodynamic therapy for neovascular age-related macular degeneration. [2010.06]

Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. [2010.06]

Polypoidal choroidal vasculopathy: an angiographic discussion. [2010.03]

[Effectivity and safety of bevacizumab intravitreal injections for exudative age-related macular degeneration treatment--6 months observations]. [2010]

Tunnelled versus straight intravitreal injection: intraocular pressure changes, vitreous reflux, and patient discomfort. [2009.09]

Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials. [2009.08]

Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. [2006.12]

Other research related to Lucentis (Ranibizumab)

Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. [2012]

Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. [2012]

Anti-VEGF therapy for the treatment of glaucoma: a focus on ranibizumab and bevacizumab. [2012]

Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization. [2012]

Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study). [2012]

Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration. [2012]

Intravitreal ranibizumab (lucentis) for the treatment of diabetic macular edema: a systematic review and meta-analysis of randomized clinical control trials. [2012]

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. [2012]

Long-term results of intravitreal ranibizumab, intravitreal ranibizumab with photodynamic therapy, and intravitreal triamcinolone with photodynamic therapy for the treatment of retinal angiomatous proliferation. [2012]

The effect of fellow eye visual acuity on visual acuity of study eyes receiving ranibizumab for age-related macular degeneration. [2012]

EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. [2012]

Vandetanib: in medullary thyroid cancer. [2012]

Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial. [2010.10.01]

Two-Year Outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study. [2010.09.18]

Ranibizumab for Choroidal Neovascularization Secondary to Causes Other Than Age-Related Macular Degeneration: A Phase I Clinical Trial. [2010.07.31]

DOSING REGIMEN AND THE FREQUENCY OF MACULAR HEMORRHAGES IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH RANIBIZUMAB. [2010.07.30]

Cost-effectiveness of ranibizumab for the treatment of neovascular age-related macular degeneration in germany: Model analysis from the perspective of germany's statutory health insurance system. [2010.07]

Aqueous vascular endothelial growth factor after intravitreal injection of pegaptanib or ranibizumab in patients with age-related macular degeneration. [2010.07]

A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration Clinical and Economic Impact. [2010.06.29]

A randomised prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration. [2010.06.25]

Neovascular Age-related Macular Degeneration: Intraocular Cytokines and Growth Factors and the Influence of Therapy with Ranibizumab. [2009.10.06]

Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor. [2009.09]

Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. [2009.09]

Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration. [2009.09]

A Phase I Study of Intravitreal Vascular Endothelial Growth Factor Trap-Eye in Patients with Neovascular Age-Related Macular Degeneration. [2009.08.21]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014